

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM protein - protein search, using sw model

Run on: September 4, 2002, 16:08:57 : Search time 165.17 Seconds
(without alignments)
316.066 Million cell updates/sec

Title: US-09-052-089a-2
Perfect score: 2393
Sequence: 1 MPILSLCTICSDFDHSDV.....VRIKTVSSASOPKLDFTLCQ 470

Scoring table:
BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 747574 seqs, 111073796 residues
Total number of hits satisfying chosen parameters: 747574

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database :

A.Geneseq_032802:.*
1: /SID55/gcgdata/geneseq/genesqp-emb1/AA1980.DAT:*
2: /SID55/gcgdata/geneseq/genesqp-emb1/AA1981.DAT:*
3: /SID55/gcgdata/geneseq/genesqp-emb1/AA1982.DAT:*
4: /SID55/gcgdata/geneseq/genesqp-emb1/AA1983.DAT:*
5: /SID55/gcgdata/geneseq/genesqp-emb1/AA1984.DAT:*
6: /SID55/gcgdata/geneseq/genesqp-emb1/AA1985.DAT:*
7: /SID55/gcgdata/geneseq/genesqp-emb1/AA1986.DAT:*
8: /SID55/gcgdata/geneseq/genesqp-emb1/AA1987.DAT:*
9: /SID55/gcgdata/geneseq/genesqp-emb1/AA1988.DAT:*
10: /SID55/gcgdata/geneseq/genesqp-emb1/AA1989.DAT:*
11: /SID55/gcgdata/geneseq/genesqp-emb1/AA1990.DAT:*
12: /SID55/gcgdata/geneseq/genesqp-emb1/AA1991.DAT:*
13: /SID55/gcgdata/geneseq/genesqp-emb1/AA1992.DAT:*
14: /SID55/gcgdata/geneseq/genesqp-emb1/AA1993.DAT:*
15: /SID55/gcgdata/geneseq/genesqp-emb1/AA1994.DAT:*
16: /SID55/gcgdata/geneseq/genesqp-emb1/AA1995.DAT:*
17: /SID55/gcgdata/geneseq/genesqp-emb1/AA1996.DAT:*
18: /SID55/gcgdata/geneseq/genesqp-emb1/AA1997.DAT:*
19: /SID55/gcgdata/geneseq/genesqp-emb1/AA1998.DAT:*
20: /SID55/gcgdata/geneseq/genesqp-emb1/AA1999.DAT:*
21: /SID55/gcgdata/geneseq/genesqp-emb1/AA2000.DAT:*
22: /SID55/gcgdata/geneseq/genesqp-emb1/AA2001.DAT:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	1826.5	76.3	469	20	AAV30149
2	1819.5	76.0	469	19	AAW37881
3	281.5	11.8	455	22	ABB61289
4	195.5	8.2	1690	22	ABB61144
5	195.5	8.2	1690	22	ABB61173
6	192.5	8.0	1325	18	AAW19540
7	192.5	8.0	1325	20	AAW94391
8	190	7.9	2056	22	ABB59344
9	188.5	7.9	574	22	AA95497
10	179.5	7.5	1968	22	AAW40999
11	179.5	7.5	1968	22	AAW41000

12	178	7.4	482	22	ABB71396
13	177	7.4	1951	22	ABG01723
14	177	7.4	1960	22	AAW78854
15	177	7.4	2143	22	ABC01716
16	176.5	7.4	1975	22	ABB62094
17	175.5	7.3	1017	22	AAE02246
18	175	7.3	1177	22	AA96721
19	174.5	7.3	875	22	AAE02245
20	174.5	7.3	878	22	AAE02242
21	174	7.3	1374	22	AA969070
22	174	7.3	1489	22	ABB59948
23	173.5	7.3	1203	22	AAW79292
24	172.5	7.2	864	22	AAW40292
25	172.5	7.2	2482	16	AAW72826
26	172.5	7.2	2482	19	AAW23996
27	172.5	7.2	3248	17	AA969795
28	172	7.2	717	21	ABB21231
29	171.5	7.2	1456	22	ABB58673
30	170.5	7.1	866	21	AAW86194
31	170.5	7.1	1752	20	AAW07031
32	170.5	7.1	1948	22	ABG21233
33	170.5	7.1	1963	22	AAW79838
34	170.5	7.1	2918	22	ABG27218
35	170	7.1	1093	14	AAW42818
36	170	7.1	2017	22	ABG06301
37	169.5	7.1	561	19	AAW63043
38	169	7.1	1090	21	AAW59270
39	168.5	7.0	560	22	AAU31067
40	168.5	7.0	576	16	AAW6929
41	168.5	7.0	731	22	AAW48573
42	168.5	7.0	816	16	AAW66931
43	168.5	7.0	885	16	AAW66930
44	168.5	7.0	2400	22	ABG20278
45	168.5	7.0	2415	22	ABG20279

ALIGNMENTS

RESULT 1	AAV30149	AAV30149 standard; Protein; 469 AA.
ID	AAV30149;	
AC	AAV30149;	
XX	27-OCT-1999	(first entry)
DE	Amino acid sequence of a BRCA1 modulator protein.	
XX	Modulator protein; BRCA1; tumour suppressor protein; breast cancer;	
KW	ovarian cancer; cell growth; cell proliferation.	
XX	Homo sapiens.	
OS	Homo sapiens.	
XX	Key	
FH	Region	Location/Qualifiers
FT	Region	3...32
FT	Region	/note="zinc finger motif"
FT	Region	230..255
FT	Region	/note="leucine zipper motif"
XX	US5948643-A.	
PN	07-SEP-1999.	
XX	13-AUG-1997;	97US-0968751.
PF	13-AUG-1997;	97US-0968751.
XX	13-AUG-1997;	97US-0968751.
PR	(ONYX-) ONYX PHARM INC.	
PA	Lingenfelter C, Polakis PG, Rubinfeld B, Vuong TM;	
PI	WPI; 1999-517952/43.	
XX		
DR		

Drosophila melanog
Novel human diago
Human protein SFO
Novel human diago
Drosophila melanog
Domestic mite Bt1
Domestic mite Bt1
Domestic mite Bt1
Human male enhance
Drosophila melanog
Human protein SFO
Human polypeptide
Human mitosis. Ho
Human mitosis. am
kinetochore protei
Tomato Lkmp1. Ly
Drosophila melanog
Nuclear transport
Breast cancer asso
Novel human diago
Human protein SFO
Novel human diago
TMF. Homo sapiens
Novel human diago
Streptococcus uber
Human huntingtin-i
Novel human secret
AMUL chromosome in
Human breast cance
AMUL chromosome in
Novel human diago
Novel human diago

DR N-PSDB: AAX86754.
 XX Modulator proteins that bind to and modulate the activity of the
 PT BRCA1 tumour suppressor gene product, useful for the treatment of
 PT ovarian and breast cancer
 XX
 XX Example 1; Fig 1; 35pp; English.

XX The present sequence represents a modulator protein, that binds to and
 CC modulate the activity of the BRCA1 gene product (BRCA1). The BRCA1
 CC protein has been characterized as a tumour suppressor protein.
 CC Alterations in the amino acid sequence of BRCA1 causes breast and ovarian
 CC cancers by removing the controls on cell growth and proliferation.
 CC Research has shown that different regions on the BRCA1 molecule have
 CC different effects on cell growth and tumour suppression (e.g. full length
 CC truncated BRCA1 has no effect on breast cancer cell growth but will
 CC inhibit ovarian cancer cell growth). It has been suggested that different
 CC host cell factors (e.g. proteins) interact with different regions of the
 CC BRCA1 to control its function. The identification of these proteins
 CC (e.g. BRCA1MP) will facilitate the development of novel diagnostic
 CC methods and new therapeutics for identifying and treating cancers caused
 CC by changes in the expression or activity of BRCA1.

XX Sequence 469 AA;

Query Match 76.3%; Score 1826.5; DB 20; Length 469;

Best Local Similarity 77.6%; Pred. No. 1,4e-147; Mismatches 363; Conservative 41; Mismatches 63; Indels 1; Gaps 1;

QY 1 MPILSLCTICSDFPDHSDVAIAHCGHTFHLQCLIQWFETAPSRPCQCRIOVGKRTIIN 60
 DB 1 mpiralcticsdfdhshdvaiahcgthfhlqcliqwfetapstpcqcritygkrtlin 60
 QY 61 KLFFDLAEEENVDAAEFKNELDVSKAQLSQKREKRDQAIIITDLRDLTEENATVES 120
 DB 61 klffdlageeenvdaeflkneldnvraqlsqkrekrdqvaidlrltleeenatvsv 120
 QY 121 LQNALNKAEMLCSTLKKOMKFLQRODETOQAREAHRLKCKMKTMEQIELLSQSEV 180
 DB 121 lqnalgaemlcstlkkqmkylleqgdektqageaartrlskmtmeqieillsqqrpev 180
 QY 181 EEMTRDMGVGOSAVEQLAVYCVSLKKEYENLKEARKATGELADRLKDLVSSRSKLTLN 240
 DB 181 eemtrdmvgosaveqlavycvslkkeyenlkearkatgadelrlldfssrsklqtv 240
 QY 241 TELDOAKLELRSAQKDLQSDQETTSLRKSDDPGMLPEPASATNETVSRIVEESPAPVE 300
 DB 241 teldoaklelrsaqkdlqsadkettslrksdppgmleppasatnetvdrvlvespave 300
 QY 301 MMNPLRHQPFPGDEIDNTFEDVNTPTQTSQSQHCLPKRLCLERARSPMONVLKVKHY 360
 DB 301 -vnlktrpfrddidlnatfdvdtpparpsqngyeyeklcteksnspiqdvpkklckg 359
 QY 361 SKPEPSLISLGQRCVGEIDELAGAPFLFRNAVLAGQKOPKRTTAESRSSTDVRIEGDG 420
 DB 360 skpesqlslgsgcagdeelvafpifvrnalilgqkqprpsesscsdvrttfdg 419
 QY 421 LGGTRKTROPRTTIIRPVYKSKAKSKOKVRITVSSASOPKIDTL 468
 DB 421 lggtrktroprttiirpvvykkskaksokvritvssasopkidlftl 467

RESULT 2

AAW37881
 ID AAW37881 standard; Protein: 469 AA.

XX AAW37881;

DT 28-AUG-1998 (first entry)

DE BRCA1 modulator protein 091-21A31.

XX

KW BRCA1 modulator protein: 091-21A31; breast cancer antigen 1;
 KW tumour suppressor protein; diagnosis; therapy; human.
 XX
 XX Homo sapiens.

FT Key Location/Qualifiers
 FT Domain 3..54 /note="zinc finger motif"
 FT Domain 229..255 /note="leucine zipper motif"

FT MO9810066-A1.

PD 12-MAR-1998.

PE 06-AUG-1997; 97WO-US13944.

PR 04-SEP-1996; 96US-0025601.

PA (ONYX-) ONYX PHARM INC.

PI Ligenfelter C, Polakis P, Rubinfeld B, Vuong TT;

DR WPI: 1998-193616/17.

DR N-PSDB: AAV29062.

PT Breast cancer antigen 1 modulator protein - useful for diagnosing
 PT diseases involving unwanted cell growth, e.g. breast cancer, and for
 PT producing therapeutics for treatment of such diseases

XX Example 1; Fig 1; 73pp; English.

XX This polypeptide comprises a 53 kDa BRCA1 modulator protein that
 CC binds to the tumour suppressor gene product BRCA1, and which is
 CC characterised by a zinc finger domain and a leucine zipper motif.
 CC Its amino acid sequence was deduced from the nucleotide sequence
 CC of a cDNA clone (see AAV29062), designated 091-21A31 (ATCC 98141),
 CC isolated from a HeLa cell cDNA library using a yeast two-hybrid
 CC assay. 3 cDNA clones (see also AAV29063-64) coding for BRCA1
 CC modulator proteins (see AAW37881-83) have been characterised. Vectors
 CC and host cells comprising the isolated nucleic acid sequences are
 CC claimed, as well as a process for producing BRCA1 modulator protein
 CC by culturing these host cells. BRCA1 modulator proteins and nucleic
 CC acids can be used to diagnose diseases involving unwanted cell
 CC growth, e.g. breast cancer, and to identify compounds that alter
 CC BRCA1 interaction with BRCA1 modulators for the treatment of such
 CC diseases.

SQ Sequence 469 AA;

Query Match 76.0%; Score 1819.5; DB 19; Length 469;

Best Local Similarity 77.4%; Pred. No. 5.6e-147; Mismatches 362; Conservative 41; Mismatches 64; Indels 1; Gaps 1;

QY 1 MPILSLCTICSDFPDHSDVAIAHCGHTFHLQCLIQWFETAPSRPCQCRIOVGKRTIIN 60
 DB 1 mpiralcticsdfdhshdvaiahcgthfhlqcliqwfetapstpcqcritygkrtlin 60
 QY 61 KLFFDLAEEENVDAAEFKNELDVSKAQLSQKREKRDQAIIITDLRDLTEENATVES 120
 DB 61 klffdlageeenvdaeflkneldnvraqlsqkrekrdqvaidlrltleeenatvsv 120
 QY 121 LQNALNKAEMLCSTLKKOMKFLQRODETOQAREAHRLKCKMKTMEQIELLSQSEV 180
 DB 121 lqnalgaemlcstlkkqmkylleqgdektqageaartrlskmtmeqieillsqqrpev 180
 QY 181 EEMTRDMGVGOSAVEQLAVYCVSLKKEYENLKEARKATGELADRLKDLVSSRSKLTLN 240
 DB 181 eemtrdmvgosaveqlavycvslkkeyenlkearkatgadelrlldfssrsklqtv 240
 QY 241 TELDOAKLELRSAQKDLQSDQETTSLRKSDDPGMLPEPASATNETVSRIVEESPAPVE 300
 DB 241 teldoaklelrsaqkdlqsadkettslrksdppgmleppasatnetvdrvlvespave 300

[illegible]

Db	6	civicelllggaddevatvctcgmmfhmncnqlwldr--sktccpgrcnkctctnnif-rvfyfnl	62
Qy	67	AOEENENVDAAEFLLKNELDSVKAQISQDKREKRSQAIIIDTRDLTEERNATVESIQNALN	126
Db	63	anldsvhidvsglqglndamlsmkwvckernkdegqirdlketqcklktiajlegqvq	122
Qy	127	KAEMLCSTLKKOMKFLBQRODETKQAREEAHRLCKKMTMEOIELLLOSQSRSEVEMIRD	186
Db	123	kKdfllssyveqigvLksadahvvdqlrkenKtlkqIsgmejsaillaagsadadrllkn	182
Qy	187	MGVGSAAVEOLAVVSVSLKKEVENLK----EARKATGELADLKLKDLVSRSEKLTLMN-	241
Db	183	----eaophvlnavstlkrclrgceskkteltrnvkvvqgnolrkelclkyahimnv	238
Qy	242	-----ELDQAKLELRSA--QKDLQADQDEITSLRKS---DDPGNLEPASATNETVSR	290
Db	239	flidmcstcdskleerthvhesldlygaqekIafenktaYldsp-----nascglnslla	294
Qy	291	LVFE-----SPAPVEMNPRILHOPFGDEIDLNTTFEDVNPPTPTSGSHCLPKK--LC	342
Db	295	lkreertltspvtvkenik-----rlseestspYnl-kssavglahlInlknlg	343
Qy	343	LERAR-SPMONVNLKKVHKVSKPESQLSGGRCVGELEDELAGAPPLFRNNAVLOKQPN	401
Db	344	IakssipLkvgvgvsmts-----gtlktssdlsekyslf-----kKpr	384
Qy	402	RTTAASRSSTVDVVRIG---FDGLGRTFTIQPRDPTTIIRPVPRKSKAKSKOKVRlKTVS	457
Db	385	lllgsssssalatgsmfnvngmggsek-----vdptraqraeeeglstlrstsal	435
Qy	458	S 458	
Db	436	s 436	
RESULT 4			
ABb61144			
ID	ABb61144	standard: Protein; 1690 AA.	
AC	ABb61144;		
XX	26-MAR-2002	(first entry)	
DT			
XX	Drosophila melanogaster polypeptide SEQ ID NO 10224.		
DE			
XX	Drosophila: developmental biology; cell signalling; insecticide;		
KW	pharmaceutical.		
KN			
OS	Drosophila melanogaster.		
XX			
PN	WO2001/1042-A2.		
XX			
PD	27-SEP-2001.		
XX			
PF	23-MAR-2001; 2001WO-US09231.		
XX			
PR	23-MAR-2000; 2000US-191637P.		
XX	11-JUL-2000; 2000US-0614150.		
XX			
PA	(PEKE) PE CORP NY.		
XX			
PI	Venter JC, Adams M, Li PWD, Myers EW;		
XX			
DR	WPI: 2001-6556860/75.		
XX	N-PSDB: ABL05247.		
PT	New isolated nucleic acid detection reagent for detecting 1000 or more		
XX	genes from Drosophila and for elucidating cell signalling and cell-cell		
XX	interactions -		
PS	Disclosure: SEQ ID NO 10224; 21pp + Sequence Listing; English.		
CC	The invention relates to an isolated nucleic acid detection reagent		

capable of detecting 1000 or more genes from *Drosophila*. The invention is useful in developmental biology and in elucidating cell signalling and cell-cell interactions in higher eukaryotes for the development of insecticides, therapeutics and pharmaceutical drugs. The invention discloses genomic DNA sequences (ABL01840-ABL16175), expressed DNA sequences (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed CC specification, but was obtained in electronic format directly from WIPO CC at ftp.wipo.int/pub/published_pcl_sequences.
XX
SQ Sequence 1690 AA:

Query Match 8.2%; Score 195.5; DB 22; Length 1690;
Best Local Similarity 22.7%; Pred. No. 2.5e-07;
Matches 110; Conservative 74; Mismatches 163; Indels 137; Gaps 20;

QY 50 RIQVGKRTIINKLFFDLAQEEENVLDLAEFLKNE-----LDSVKAQLSQKDRKRDQAI 103
DB 724 qiqlekesieqglal-----kqnele-dfqkkgesevhlqelaaqntqkdfelvesges 777
QY 104 IDTLRDLTEERNATVESIQNALNKAEMLCSTLKROM-FLERODETQOAREBAHRLCK 162
DB 778 lklqqgqlqegltlghelkqaaee-----lkketelikeqelqqlqsksaesesa 830
QY 163 MKTME-QIELLLQSORSEVEEMIRDMGVGSAVEQLAVYC-----VSLKKEYNL-----KE 213
DB 831 lkvqvqqlqegiqgqaaageegsktvaklhdeisqlksqaetqselkstqsnleakskq 890
QY 214 ARKATGELADRLKKD--LVSSRSKLKTLNTELDQAKLELRSAOKDLSADODEITSLRKKS 271
DB 891 leaangslaeaakskshllqegltklk---sevgelqaaalschtdvesktkq----- 939
QY 272 DDPPGNLEPASATNETVSRVLFESPA-----PVEEMNPRLLHO----- 308
DB 940 -----leaanaalekvkneyaesraeasdlqdkvkeltldlhelqaeerssalhlk1 993
QY 309 PPFGDEI-----DLNTTFDVNTPTQTSGSOHCLPKKLCLERRASPMQ----- 351
DB 994 skfidelatqhkeltskad-----awsgemlqkekelqelqqlqdsqsgtklkae 1045
QY 352 -----NVLKKVHKVSKPESQLSLGQRCVGEDELDELAGAPFLFIRNAVIGOK 398
DB 1046 gerkeksfeesiknlqeevtaktenlelstqgtcttkldigerle-----itnaelqhk 1099
QY 399 QPNRTTAEBSSTDVVRIGFDGLGRTFTIQPRD-TTIIRVPVSKSAKSKQKVRIRKTVS 457
DB 1100 -----ekmasedaqkia-----dlktlveaigvananisaetnaelstvl 1138
QY 458 SASQ 461
DB 1139 evlq 1142

RESULT 5
ABB61173
ID ABB61173 standard; protein; 1690 AA.
XX
AC ABB61173;
XX
DT 26-MAR-2002 (first entry)
XX
DE *Drosophila melanogaster* polypeptide SEQ ID NO 10311.
XX
KW *Drosophila*; developmental biology; cell signalling; insecticide;
XX
OS *Drosophila melanogaster*.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.

XX 23-MAR-2001; 2001WO-US09231.
XX
XX 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
XX (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW.
XX
XX WPI; 2001-656860/75.
DR N-PSDB; ABL05276.
XX
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from *Drosophila* and for elucidating cell signalling and cell-cell
PT interactions -
PS
XX Disclosure; SEQ ID NO 10311; 21pp + Sequence Listing; English.

The invention relates to an isolated nucleic acid detection reagent capable of detecting 1000 or more genes from *Drosophila*. The invention is useful in developmental biology and in elucidating cell signalling and cell-cell interactions in higher eukaryotes for the development of insecticides, therapeutics and pharmaceutical drugs. The invention discloses genomic DNA sequences (ABL01840-ABL16175), expressed DNA sequences (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed CC specification, but was obtained in electronic format directly from WIPO CC at ftp.wipo.int/pub/published_pcl_sequences.
XX
SQ Sequence 1690 AA:

Query Match 8.2%; Score 195.5; DB 22; Length 1690;
Best Local Similarity 22.7%; Pred. No. 2.5e-07;
Matches 110; Conservative 74; Mismatches 163; Indels 137; Gaps 20;

QY 50 RIQVGKRTIINKLFFDLAQEEENVLDLAEFLKNE-----LDSVKAQLSQKDRKRDQAI 103
DB 724 qiqlekesieqglal-----kqnele-dfqkkgesevhlqelaaqntqkdfelvesges 777
QY 104 IDTLRDLTEERNATVESIQNALNKAEMLCSTLKROM-FLERODETQOAREBAHRLCK 162
DB 778 lklqqgqlqegltlghelkqaaee-----lkketelikeqelqqlqsksaesesa 830
QY 163 MKTME-QIELLLQSORSEVEEMIRDMGVGSAVEQLAVYC-----VSLKKEYNL-----KE 213
DB 831 lkvqvqqlqegiqgqaaageegsktvaklhdeisqlksqaetqselkstqsnleakskq 890
QY 214 ARKATGELADRLKKD--LVSSRSKLKTLNTELDQAKLELRSAOKDLSADODEITSLRKKS 271
DB 891 leaangslaeaakskshllqegltklk---sevgelqaaalschtdvesktkq----- 939
QY 272 DDPPGNLEPASATNETVSRVLFESPA-----PVEEMNPRLLHO----- 308
DB 940 -----leaanaalekvkneyaesraeasdlqdkvkeltldlhelqaeerssalhlk1 993
QY 309 PPFGDEI-----DLNTTFDVNTPTQTSGSOHCLPKKLCLERRASPMQ----- 351
DB 994 skfidelatqhkeltskad-----awsgemlqkekelqelqqlqdsqsgtklkae 1045
QY 352 -----NVLKKVHKVSKPESQLSLGQRCVGEDELDELAGAPFLFIRNAVIGOK 398
DB 1046 gerkeksfeesiknlqeevtaktenlelstqgtcttkldigerle-----itnaelqhk 1099
QY 399 QPNRTTAEBSSTDVVRIGFDGLGRTFTIQPRD-TTIIRVPVSKSAKSKQKVRIRKTVS 457
DB 1100 -----ekmasedaqkia-----dlktlveaigvananisaetnaelstvl 1138
QY 458 SASQ 461
DB 1139 evlq 1142

```

RESULT 6
AAW19540
ID AAW19540 standard; Protein; 1325 AA.
XX
AC AAW19540;
XX
DT 16-SEP-1997 (first entry)
XX
DE Male-enhanced antigen-2.
XX
KW Mouse; MEA-2; detecting mutation.
XX
OS Mus musculus domesticus.
XX
FH Key Location/Qualifiers
FT MISC-difference 305..320
FT /note= "Not shown in the specification"
XX
PN JP09121869-A.
XX
PD 13-MAY-1997.
XX
PF 07-NOV-1995; 95JP-0311638.
XX
PR 07-NOV-1995; 95JP-0311638.
XX
PA (ITOH-) ITO HAM KK.
XX
WP1: 1997-314229/29.
DR N-PSDB; AAT74034.
XX
PT Male-enhanced antigen Mea-2 gene - especially from mouse, useful for
PT detecting mutation(s)
XX
PS Claim 8; Page 9-10; 13pp; Japanese.
XX
CC The present sequence represents male-enhanced antigen-2 (MeA-2), which
CC has been derived from a domestic mouse. The polynucleotide encoding
CC the protein can be used for the detection of mutations affecting the
CC MEA-2 gene.
XX
SQ Sequence 1325 AA;

Query Match 8.0%; Score 192.5; DB 18; Length 1325;
Best Local Similarity 22.4%; Pred. No. 3.2e-07;
Matches 94; Conservative 80; Mismatches 156; Indels 89; Gaps 16;

OY 65 DLAEENAVLDA-EFLKNE-----LDYKAOQSQRDKR-----DSQAIIITLRLD 109
DB 590 elgreadsredaiflqnekivlevalqsakskdeeldrgarrlleedteetsgllqrlq 649
OY 110 TLEERNATVESLQNALNKAEMLCSTLKKOM-----KPLEQ-----RODET-----KQ 151
DB 650 dlawksngvehlqge-----tatlirkqmqkvkeqfvgqvmvweayrtdatskdqlne 702
OY 152 AREBAHRLKCKMKTMEQIELLQSORSEVE-----EMIRDMGVGOSAVQQLAVYCVSLKKE 207
DB 703 lkatckkridsemkelrgeflklqgekkvvehsrlqkdmelivhgmmeleghlqsvyqke 762
OY 208 YEN-----LKEA-----RKATGELADRLKLDVSSRSKLTLTNTELDQA 246
DB 763 rdemeihlqslkfdkegmialteanetlkqgleelqgeakkaiteqkqkmlrlgsdlisa 822
OY 247 KLELRSACKDQADQOETISLRKKSDDPPGNLEPASATNETVSRLLVFESPAPEVEMMNR 306
DB 823 qkemtkhkyena---vsilstrlqea---laskaeatdaelnqraqstg--gsadpvl 874
OY 307 HQPRGDEIDINTT-----FDVNTPTPTQTSQS--QHCLPKKCLLEKARSPMOMVLLKV 357
DB 875 hekiralavehqnvgakilllekelqevlmtlsgelesrekxvleledelelgesirgfrk 934

```

```

OY 358 HKVSKPESQSLSGORCVGELEELAGAPFLIRNAVLAGOKOPNRTAESRSSSTDVRI 416
DB 935 krleesnkklal-----elehergklitglgsnaalrehnsllevalakreadlrvql 986

RESULT 7
AAW94391
ID AAW94391 standard; Protein; 1325 AA.
XX
AC AAW94391;
XX
DT 14-APR-1999 (first entry)
XX
DE Mouse male enhanced antigen 2.
XX
KW Mouse; male enhanced antigen 2; Mea-2; Mus musculus domesticus;
KW spermatogenesis; regulation; contraceptive; sterile; inhibition.
XX
OS Mus sp.
XX
PN JP11018622-A.
XX
PD 26-JAN-1999.
XX
PF 04-JUL-1997; 97JP-0179490.
XX
PR 04-JUL-1997; 97JP-0179490.
XX
PA (ITOH-) ITO HAM KK.
XX
WP1: 1999-160962/14.
DR N-PSDB; AAX04132.
XX
PT Regulation of spermatogenesis using Mea-2 gene information - using
PT anti-sense oligo- or poly:nucleotide(s), used for production of
PT contraceptives
XX
PS Claim 4; Page 8-12; 27pp; Japanese.
XX
CC The present sequence represents mouse male enhanced antigen 2 (Mea-2).
CC The present invention describes the regulation of spermatogenesis by
CC using Mea-2 information. A non-human living organism can have its
CC spermatogenesis inhibited by breakage of the whole or part of the Mea-2
CC gene. Also described are: (1) the creation of the spermatogenesis-
CC inhibited organism; (2) a drug composition containing an oligonucleotide
CC or polynucleotide containing base sequences that pair with at least part
CC of the Mea-2 gene and are able to inhibit the expression of Mea-2 gene;
CC and (3) the creation of an aimed gene-possessing organism using the
CC spermatogenesis inhibited organism. The organism is useful for producing
CC contraceptive drugs.
XX
SQ Sequence 1325 AA;

Query Match 8.0%; Score 192.5; DB 20; Length 1325;
Best Local Similarity 22.4%; Pred. No. 3.2e-07;
Matches 94; Conservative 80; Mismatches 156; Indels 89; Gaps 16;

OY 65 DLAEENAVLDA-EFLKNE-----LDYKAOQSQRDKR-----DSQAIIITLRLD 109
DB 590 elgreadsredaiflqnekivlevalqsakskdeeldrgarrlleedteetsgllqrlq 649
OY 110 TLEERNATVESLQNALNKAEMLCSTLKKOM-----KPLEQ-----RODET-----KQ 151
DB 650 dlawksngvehlqge-----tatlirkqmqkvkeqfvgqvmvweayrtdatskdqlne 702
OY 152 AREBAHRLKCKMKTMEQIELLQSORSEVE-----EMIRDMGVGOSAVQQLAVYCVSLKKE 207
DB 703 lkatckkridsemkelrgeflklqgekkvvehsrlqkdmelivhgmmeleghlqsvyqke 762
OY 208 YEN-----LKEA-----RKATGELADRLKLDVSSRSKLTLTNTELDQA 246

```

Db 763 rdemeihqskfxfkbgmialteanetlkkqieelgqeakkaatebqqkmkljgsdlisa 822

Oy 247 KLELRSAKDQASADOEITSLRKSSDDPPGNTLSPASATNETVSRULFEESPAPVEEMNRL 306
 |::: |::: |::: |::: |::: |::: |::: |::: |::: |:::
Db 823 qkemtkkhayena---vslsrllgea---laskeatdaelnqlragtg--gssdplv 874

Oy 307 HQPFGDEIDANTT-----FDVNTPPTQTSGS-QHCLPKKLCLEARSPMOMLVKKV 357
 |::: |::: |::: |::: |::: |::: |::: |::: |::: |:::
Db 875 hektrallevelgnvgasklllekelgevltmtsqeleesrekyldeledgesrgfrki 934
 |::: |::: |::: |::: |::: |::: |::: |::: |::: |:::

Oy 358 HKVSKPEQSOLSGORCVGEIDEELAGAFPLFRNMVLGOKOPNRTTAESRSTQVVR 416
 |::: |::: |::: |::: |::: |::: |::: |::: |::: |:::
Db 935 krleesnkklal-----elehergkltlgqgsnaalehtremsllatakradlvql 986

RESULT 8
ABB59344
ID ABB59344 standard; Protein; 2056 AA.
XX
AC ABB59344;
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 4824.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
XX pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN MO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001MO-USO9231.
XX
PR 23-MAR-2000; 2000US-191637P.
XX PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EM;
XX
DR MPI: 2001-656860/75.
XX N-PDB: ABL03447.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure; SEQ ID NO 4824; 21pp + Sequence Listing; English.
XX
CC The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL01840-ABLI6175), expressed DNA
CC sequences (ABL01840-ABLI6175) and the encoded proteins
CC (ABB57737-ABB72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at fltp.wipo.int/pub/published_pct_sequences.

Sequence 2056 AA:
QQ

```

Db 1302 ktvlek-----akvllaenaadlatelrsvnsrgendfrrkqaesqjaelqvklae 1353
Oy 1104 IDTRDLTLEER---NATVESLONALNKAEMLCSTLKOKMKFLEROOETFOAREEAHR- 158
Db 1354 Ierarselgeckctklqgaenitnqlneeeakasaavksasmesqllceaqllleetrq 1413
Oy 159 ---LCKMKWTMEOTELLLOSORSEVEBMTIDMGVGSASVQLAVYCVLKKREYENLKEAR 215
Db 1414 klqjsrkirgjesekaelqleeddeakrny---erklaevltqmgakkkhaeedadia 1470
Oy 216 KATGELMDRLKXDLVSSRSKLTKL---NNEIDQAKLELRSACKD---LOSADDEITSR 268
Db 1471 kelaegkkrlnkkdleaerlvkeliagnrldkskkklqseldebtlaeaaqrntele 1530
Oy 269 KKSDDPCGNLEPASATNETVSRVLFPESPAPVEIMNRLHQPFGEIDILNTTTPVFNPPPT 328
Db 1531 kkgk----nfklllaekaaesqjaqerdtlaearekctkylsvrsleideaft----- 1580
Oy 329 QTSQSQHCLPKKLCLERASPMQNVL-----KKVHKVSNP-----ESQLS-LGGQ 372
Db 1581 -----kiedlenkrktlqneiddlanctgadtakrvhelaekakralsesqjaelkag 1630
Oy 373 RCVGELDEEL 382
Db 1631 n--eeleddl 1638

```

CC	RESULT	9
CC	AAB95497	
CC	ID	AAB95497 standard; Protein; 574 AA.
CC	AC	
CC	AAB95497;	
CC	XX	
CC	DT	26-JUN-2001 (first entry)
CC	XX	
CC	DE	Human protein sequence SEQ ID NO:18041.
CC	XX	
CC	KW	Human; primer; detection; diagnosis; antisense therapy; gene therapy.
CC	XX	
CC	OS	Homo sapiens.
CC	XX	
CC	PN	EP1074617-A2.
CC	PD	07-FEB-2001.
CC	XX	
CC	PE	28-JUL-2000; 2000EP-0116126.
CC	XX	
CC	PR	29-JUL-1999; 99JP-0248036.
CC	PR	27-AUG-1999; 99JP-0300253.
CC	PR	11-JAN-2000; 2000JP-0118776.
CC	PR	02-MAY-2000; 2000JP-0183767.
CC	PR	09-JUN-2000; 2000JP-0241899.
CC	XX	
CC	PA	(HELI-) HELIX RES INST.
CC	PI	Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J;
CC	PI	Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T;
CC	XX	
CC	DR	WPI: 2001-318749/34.
CC	XX	
CC	PT	Primer sets for synthesizing polynucleotides, particularly the 5602
CC	PT	full-length cDNAs defined in the specification, and for the detection
CC	PT	and/or diagnosis of the abnormality of the proteins encoded by the
CC	PT	full-length cDNAs -
CC	XX	
CC	XX	
CC	PS	Claim 8; SEQ ID 18041; 2537p + CD ROM; English.
CC	XX	
CC	CC	The present invention describes primer sets for synthesizing 5602
CC	CC	full-length cDNAs defined in the specification, where a primer set
CC	CC	comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC	CC	to the complementary strand of a polynucleotide which comprises one of
CC	CC	the 5602 nucleotide sequences defined in the specification, where the
CC	CC	oligonucleotide comprises at least 15 nucleotides; or (b) a combination

Db 1795 sdnarqqlerqnlkalklqelqegavkskfkatlsaleakigleq 1842

RESULT 11

AA041000 standard; Protein; 1988 AA.

AA041000;

22-OCT-2001 (first entry)

Human polypeptide SEQ ID NO 5931.

Human; nocotropic; immunosuppressant; cytostatic; gene therapy; cancer; peripheral nervous system; neuropathy; central nervous system; CNS; Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic; amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic; chemokinetic; thrombolytic; drug screening; arthritis; inflammation; leukaemia.

Homo sapiens.

MO20015312-A1.

26-JUL-2001.

26-DEC-2000; 2000MO-US34263.

21-JAN-2000; 2000US-0488725.

25-APR-2000; 2000US-0552317.

09-JUL-2000; 2000US-0598042.

19-JUL-2000; 2000US-0620312.

03-AUG-2000; 2000US-0653450.

14-SEP-2000; 2000US-0662191.

19-OCT-2000; 2000US-0693036.

29-NOV-2000; 2000US-0727344.

WPI: 2001-442253/47.

N-PSDB; AAI60156.

Example 2; SEQ ID NO 5931; 10078pp; English.

Novel nucleic acids and polypeptides, useful for treating disorders such as central nervous system injuries -

The invention relates to human nucleic acids (AA157798-AA161365) and the encoded polypeptides (AA038642-AA042213) with nocotropic,

immunosuppressant and cytostatic activity. The polynucleotides are useful in gene therapy. A composition containing a polypeptide or polynucleotide

of the invention may be used to treat diseases of the peripheral nervous system, such as peripheral nervous injuries, peripheral neuropathy and

localised neuropathies and central nervous system diseases, such as Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic

lateral sclerosis, and Shy-Drager Syndrome. Other uses include the utilisation of the activities such as: Immune system suppression,

Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, cancer diagnosis and therapy, drug screening,

assays for receptor activity, arthritis and inflammation, leukaemia and C.N.S disorders.

Note: The sequence data for this patent did not form part of the printed specification.

Sequence 1988 AA;

Query Match

7.5%; Score 179.5; DB 22; Length 1988;

Best Local Similarity 21.8%; Pred. No. 7.4e-06; Matches 76; Conservative 77; Mismatches 140; Indels 55; Caps 10;

QY 68 QEEENVDAEFLEKNELDVKAOLSKDKREKRDQAIIIDTLDTLEERATVESIQNLNK 127

Db 1517 qnkqlradmedlmskddvgnkvnelekskralqeqveemtlqleedqlqatedaklr 1576

QY 128 AEMLCSTLKQKMKFLEORODE-----TKQAREEAHRLCKMK-----TMEQTEL 171

Db 1577 levmngamkqdferrdlqtrdneqnekrlllkqyrelaeaelederkqalavaakkmel 1636

QY 172 LIGSORSEFE--EMIRMGVGSAAVEQLAVYCVSLKREYENLKEARKATGELADRLKDL 229

Db 1637 dlkdlaeqleaaankard-----evikqlrkqkqdkdygreleearasrdeifagske-- 1689

QY 230 VSSRSKLTLTLELDQALELRSAQKDSQSDQETLSLRKSDPPGLERASATNETVS 289

Db 1690 --sekklkslaaelllqleelasserarrhaeqerdel--adeltnsaqksalldkr 1744

QY 290 RL-----VFESPAPVEMMNPRLHOPPFGEIDLTFTFDVNTPTORTSGSOHCLPK 339

Db 1745 rleariagleeleeeegsmelndfrfk-----tlqydtlnaelaaersaak 1794

QY 340 ----KLCLEARSPQWNLKRVKRVKSPESQLSLGG-QRCVGELEDEL 382

Db 1795 sdnarqqlerqnlkalklqelqegavkskfkatlsaleakigleq 1842

RESULT 12

ABB71396 standard; Protein; 482 AA.

ABB71396;

26-MAR-2002 (first entry)

Drosophila melanogaster polypeptide SEQ ID NO 40980.

Drosophila; developmental biology; cell signalling; insecticide; pharmaceutical.

Drosophila melanogaster.

MO200171042-A2.

27-SEP-2001.

23-MAR-2001; 2001MO-US09231.

23-MAR-2000; 2000US-191637P.

11-JUL-2000; 2000US-0614150.

WPI: 2001-656860/75.

N-PSDB; ABL15499.

(PEKE) PE CORP NY.

Venter JC, Adams M, Li PWD, Myers EW;

New isolated nucleic acid detection reagent for detecting 1000 or more genes from Drosophila and for elucidating cell signalling and cell-cell

interactions -

Disclosure: SEQ ID NO 40980; 21pp + Sequence Listing; English.

The invention relates to an isolated nucleic acid detection reagent capable of detecting 1000 or more genes from Drosophila. The invention is

useful in developmental biology and in elucidating cell signalling and cell-cell interactions in higher eukaryotes for the development of

insecticides, therapeutics and pharmaceutical drugs. The invention discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA

sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-ABB72072).

CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 482 AA:

Query Match 7.4%; Score 178; DB 22; Length 482;
Best Local Similarity 20.0%; Pred. No. 1.3e-06;
Matches 74; Conservative 56; Mismatches 96; Indels 144; Gaps 14;

QY 4 LSLCTTSDFFDHSRD-VAAIHGCHTHLQCLIQWFTAPSRCTPCQR-----50
DB 172 lptcvclermdesvdgvltilcnhaasclmkgds---tcpcvchvqtpglvedsv 227
QY 51 -----IQVGRKTI-----INK 61
DB 228 cmecegtasjwclcgshvcgrgqyghaaahfratnhtfamtqigtssvwdyagdnfvr 287
QY 62 LFPDLAEEENVLDAEFLKNEELDSVKAKLSQDKREKRDSQAIIPTLRLDLEERNATVESTL 121
DB 288 lf-----qkhsdgklv-----asqtekd-----ereekidsm 314
QY 122 QNALNKAEMLCSTLKQKMFLEQRQDFTKQA---REBAHRLCKMKTMEQIELLOQSOR 177
DB 315 q--meftylltsqldtqrkyeermerlegewgnhkataandakevselqqlqgmqkek 372
QY 178 SEVEEMIRDMQVGSNAVEQLAVYCVSLKKEEENLKEARKKATGELADLKLKDLVSSRSKLK 237
DB 373 vnl-----rklaghtaklkdvqgkqlneer-----elskalqnsqswghkyk 415
QY 238 TLNTELDQAKLELRSAOKDLOQADQETISLRKKSDD-----PPGNLEPASATNETV 288
DB 416 llsegqyefk-----qthdaevtelkeqrdimflndinqkqlanteiaag---tv 462
QY 289 SRLVESPPAP 298
DB 463 tglaekepdp 472

RESULT 13

ABG01723
ID ABG01723 standard; Protein; 1851 AA.

AC ABG01723;

DT 13-FEB-2002 (first entry)

DE Novel human diagnostic protein #1714.

KM Human; chromosome mapping; gene mapping; gene therapy; forensic;
KW food supplement; medical imaging; diagnostic; genetic disorder.

OS Homo sapiens.

PN WO200175067-A2.

PD 11-OCT-2001.

PE 30-MAR-2001; 2001WO-0508631.

PR 31-MAR-2000; 2000US-0540217.

PR 23-AUG-2000; 2000US-0649167.

PA (HXSF-) HXSEQ INC.

PI Drmanac RT, Liu C, Tang YT;

DR WPI: 2001-639362/73.

DR N-PSDB; AAS65910.

PT New isolated polynucleotide and encoded polypeptides, useful in
PT diagnostics, forensics, gene mapping, identification of mutations

PT responsible for genetic disorders or other traits and to assess
PT biodiversity

PS Claim 20: SEQ ID No 32082; 103pp; English.

CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.

SQ Sequence 1851 AA:

Query Match 7.4%; Score 177; DB 22; Length 1851;
Best Local Similarity 21.5%; Pred. No. 1.1e-05;
Matches 109; Conservative 83; Mismatches 188; Indels 128; Gaps 19;

QY 12 DFDHSDRVAAIHGCHTHLQCLIQWFTAPSRCTPCQRQVQKTIINKLFPDLAEE 71
DB 1049 dtdltdsqiaelqghrgdaagqergagppgpppenkaekkr-----dlgele 1100
QY 72 NVLDAEFLKNEELDSVKAKLSQDKREKRDSQAIIPTLRLDLEERNATVES-LQNALNKAE 130
DB 1101 -alkte-ledtldstaag-qelrskrege--vnlkkltleeaaklheaqlqemqrghsq 1154
QY 131 LNSTLKQKMFLEQRQDFTKQAAREBAHRLCKMKTMEQIELLOQSORSEVEEMIRDMGV 189
DB 1155 aveelaeg]-----eqtrrvkanlekakgtlen-ergelanevkrkkveaqqlqykv 1206
QY 190 ---GQSAVEQLAVYCVSLKKEEYEN-----LKEARKATGELADRL 225
DB 1207 fnegervrreladkvrlqyelldnvpqllsqdsksaklckdfsaesqldtqellqee 1266
QY 226 KKDLYSSRSKRLTNTELDQAKLELRSAOKDLOQADQETISLRKKSDDPPGNLEPASATN 285
DB 1267 nrqlsistkrlkqlseeeekhn]---ekqiallhqvadamkkkmedsvgcletaeavk 1323
QY 286 -----ETVSRLVESPPA---PYEMNMPRLHQPPEFDEIDLN-----TTFD 322
DB 1324 rklqkdlqslglsqrheekvaaydklekttrlgqlddlldvldhqrsgaenlekqkxf 1383
QY 323 VNPPTOTSGSQH-----CLPKKLCLERA---RSPMQ 351
DB 1384 qlaaekltisakyaeeerdraeeareketkalslaraeeameqkaelerlnkqfeme 1443
QY 352 NVL-----KKVHKVSKPESQSLSGQORC---GGEIDELIAGAFPIFIRNAV----- 394
DB 1444 dlmskddvqksvhelestrakaleqgvveemktgleeledelqatedaklilevnlqamka 1503
QY 395 -----LGQKQPNRTTAESRSSTDVRI 416
DB 1504 qferdlqgrdepergeeeaaqgtaikql 1531

RESULT 14

AAM78854

polypeptide (II) sequences. (I) s useful as hybridisation probes, polymerase chain reaction (PCR) primers, oligomers, and for chromosome and gene mapping, and in recombinant production of (II). The polynucleotides are also used in diagnostics as expressed sequence tags for identifying expressed genes. (I) is useful in gene therapy technique to restore normal activity of (II) or to treat disease states involving (II). (II) is useful for generating antibodies against it, detecting or quantitating a polypeptide in tissue, as molecular weight markers and as a food supplement. (II) and its binding partners are useful in medical imaging of sites expressing (II). (I) and (II) are useful for treating disorders involving aberrant protein expression or biological activity. The polypeptide and polynucleotide sequences have applications in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits to assess biodiversity and to produce other types of data and products dependent on DNA and amino acid sequences. ABG0010-ABG30377 represent novel human diagnostic amino acid sequences of the invention.

Note: The sequence data for this patent did not appear in the printed specification, but was obtained in electronic format directly from WIPO at [ftp.wipo.int/pub/published_pat_sequences](http://wipo.int/pub/published_pat_sequences).

SQ Sequence 2143 AA;

Query Match	7.48	Score 177	DB 22	Length 2143
Best Local Similarity	19.08	Pred. No. 1.4e-05		
Matches 107	Conservative 114	Mismatches 181	Indels 160	Gaps 21

```

0Y 48 OCRIOWGKTTIKTFEPDIAOEENV-----LDAEF--LKNNLSVKKQLOSOX 93
Db 1155 etlkmjtlakke--eejgaalaaaveeeaaqkmalikkireeegisiseqdeleesersnka 1212
0Y 94 DREKRDSQAIIIDTLKDTLEERNATVESIONALNKAEMLCSTJLK-----QMKFTLOQ 144
Db 1213 ekqrdldgeeleaklteteldtdstaagelrskregevnllkltleeeakcheagiqem 1272
0Y 145 RO-----DETQARBEAHRKCKM---KTYE-----OIETLLQS-----ORSEV 180
Db 1273 rtkhagaaveelaegleqtkrvkanlekakqtleneergelanevkvllggkgdsenkrkv 1332
0Y 181 EEMIDMGV-----GOSAVBOLAVVCVSLKKEVENLEAKKATGELADRLKPLVYSRSKL 236
Db 1333 eeqldelgvkfnegevrvteladkyvklqveladnvqlllsgdskskltkdfsaesqj 1392
0Y 237 K-----TLNTELDQAKLELRSAAOKDQASADQ-----EITSRH 268
Db 1393 qdtgelldgeenrqxlstetklkvedeknsfregleeeceahnlkqatlhagyaadm 1452
0Y 269 KKSDDPPGNLEPASAATN-----ETVSRLVYESPA---PVEMMNRLHOPPGDEIDIN 318
Db 1453 kmedsvgletaeevkrklqkldleqlsqrheekvaaykltketrllqelddllvldid 1512
0Y 319 -----TTFDVNTPPTQSGSOH-----CLP 338
Db 1513 hqrgaecnlekkqkfdqllaeektisaayaeerdaaeeareketkalslraaleeane 1572
0Y 339 KRLICEERA---RSPQONV-----KKVHKVSPESQSLSGGRC---VGEIDPEELAG 384
Db 1573 qkaaeerlnkgrfitemeddmsskdvdgykvhbelekstrlbeqvveemkqjleedeiqja 1632
0Y 385 AEPLEIRNAVLGOKOPNRTTAAESSTDVVIRIGFDGLGRFTFIOPRDITIRPV--PVKS 443
Db 1633 tedakrlrliev-----njqamkaqferd-----lgrdqseekkqqlvrgvremea 1678
0Y 444 KAKSKOKVAKIKTVSSASOPKLD 465
Db 1679 elederkqgrsmavaarkkklemd 1700

```

RESULT 16
ABB62094
ID ABB62094 standard; Protein; 1975 AA
XX

AC ABB62094,
XX
DT 26-MAR-2002 (first entry)
XX
DE Drosophila melanogaster polypeptide SEQ ID NO 13074.
XX
KW Drosophila; developmental biology; cell signalling; insecticide;
KW pharmaceutical.
XX
OS Drosophila melanogaster.
XX
PN WO200171042-A2.
XX
PD 27-SEP-2001.
XX
PF 23-MAR-2001; 2001WO-US09231.
XX
PR 23-MAR-2000; 2000US-191637P.
PR 11-JUL-2000; 2000US-0614150.
XX
PA (PEKE) PE CORP NY.
XX
PI Venter JC, Adams M, Li PWD, Myers EW;
XX
DR WPI: 2001-656860/75.
DR N-PSDB; ABL06197.
XX
PT New isolated nucleic acid detection reagent for detecting 1000 or more
PT genes from Drosophila and for elucidating cell signalling and cell-cell
PT interactions -
XX
PS Disclosure: SEQ ID NO 13074; 21pp + Sequence Listing; English.
XX
XX The invention relates to an isolated nucleic acid detection reagent
CC capable of detecting 1000 or more genes from Drosophila. The invention is
CC useful in developmental biology and in elucidating cell signalling and
CC cell-cell interactions in higher eukaryotes for the development of
CC insecticides, therapeutics and pharmaceutical drugs. The invention
CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC sequences (ABR57737-ABR72072).
CC (ABR57737-ABR72072).
CC The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 1975 AA;

Query Match	7.48;	Score 176.5;	DB 22;	Length 1975;
Best Local Similarity	22.48;	Pred. No. 1.3e-05;		
Matches 87; Conservative	68;	Mismatches 139;	Indels 95;	Gaps 15;

```

0Y 48 OORIOVGC-KTIIINLFEPDLAOEEENVLDIAEFLKJNELDSVKROLQSOJKDEKDS--QAIID 105
Db 146Z rodaklrgkqgimlrl-----qeeksnletd-rkmksiaiga-leeklkhndecqmire 1514
0Y 106 TLRDITLERNATIVE--SLONALNKAEMLCSTFLKQMKFLEGRDODETQWQAREAHRLKCK 162
Db 1515 riagtemqjaatsengngneerleksrsgqskldnekr--qlgelaelavvegastleq 1571
0Y 163 MKTME---QIFELLOSQSEVEEEMIRDMGVGQSQSAVEOLAVYCVSLKKEKREMLKEARKRT 218
Db 1572 ryamegdlrlrlgmajqekcsirgmaerleenguraltqgldetcaikstsvqjke----- 1626
0Y 219 GELDARLKKDLVY---RSKILKTLWTELDQK-----KLELRSQAKODLOSADOETISLR 268
Db 1627 -----rlqgsavseqrlgeiktikqlkeiseghcsqanedkiklvgksiqtaeneekrilt 1681
0Y 269 KKSDDPGGLERASATNEVSRVLESAPRVEMMNPRLQHPFGGEIDINTFEDVNTPTPT 328
Db 1682 erlidsaqutlneirrsq-----a 1700
0Y 329 QTSGSOHCILPKKLCIERAHSPMQNYLK--KVHVKSPESOLSLAGORCVGELDEELIAGAF 386

```


PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
XX
DR WPI: 2001-476283/51.
DR N-PSDB: AAK53397.
XX
PT Nucleic acids encoding polypeptides with cytokine-like activities,
PT useful in diagnosis and gene therapy -
XX
PS Claim 20: Page 4327-4329; 6221pp: English.
XX
CC The invention relates to polynucleotides (AAK51456-AAK53435) and the
CC encoded polypeptides (AAM80302) that exhibit activity elating to
CC cytokine, cell proliferation or cell differentiation or which may induce
CC production of other cytokines in other cell populations. The
CC polynucleotides and polypeptides are useful in gene therapy, vaccines or
CC peptide therapy. The polypeptides have various cytokine-like activities,
CC e.g. stem cell growth factor activity, haematopoiesis regulating
CC activity, tissue growth factor activity, immunomodulatory activity and
CC activin/inhibin activity and may be useful in the diagnosis and/or
CC treatment of cancer, leukaemia, nervous system disorders, arthritis and
CC inflammation.
CC Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK53582) and 3666
CC (AAM80020) are omitted as the relevant pages from the sequence listing
CC were missing at the time of publication.
XX
SQ Sequence 1203 AA:

Query Match 7.3% Score 173.5; DB 22; Length 1203;
Best Local Similarity 21.0%; Pred. No. 1.2e-05;
Matches 96; Conservative 80; Mismatches 181; Indels 101; Gaps 15;

QY 17 SRDVAIHGHTFHLCLOHFEFAPSPKPCQCRIOVSKKTIINKLFDFDLQOEENVIDA 76
DB 650 sgevaqtrhdreleqlavilveadrgreleqnlqiklqrlqrdceaskakmva 709
QY 77 EF-----LKNELDSVKAOLSKDKREKDSQAID-----TLRDTLEE 113
DB 710 eatylqgravaetllretgeendeffrillqleqkeltqylvdggaavearlrdklyr 769
QY 114 RNATVESLONLKAEMLCSTLKROMKFLQRODETKO--AR--EAAHRLCKMKMTMOI 169
DB 770 leaekqgleealnsggeeglaaakralleaagqlarlqgeqqlnrraleeqk 829
QY 170 ELLQSQRSVEEMIRMG-----VGOSAVDQLAVYCVSLKKEENLKEARKA 217
DB 830 revlrrgkaeleeqkllldrtvdlnlkelekgedsqalq---qlaqledyke--ka 883
QY 218 TGEIAD-----RLKDLVSSRSKLTNTLMDQAKLELSAQKDL 257
DB 884 rrevadqgrqakvaseaektsqslrldqelqrlqalqsgqerdarldkelaql 943
QY 258 QSAOQETSLRKKSDDPPGNLEPASAATNEVSRLL--VFESPAVEMMNPRLHQPFGDE 314
DB 944 qglegeeenkkrsgddrarqik---gleekvrlteldeeknvelldivrg--rdq 998
QY 315 ID-LNTFFDVNTPTQYSGSQHCLPKKLCLEARSQMNVLKVKHVSRRPSQSLGGR 373
DB 999 vdqrltel-----mgersaqdlecdklslergnkdiktrlassseqfgkpsasiss----- 1048
QY 374 CVGELDELAGAPFLFIRNAVLGQKOPNRTTAESRSST 411
DB 1049 ---qlesq-----ngllqerlgaerekt 1069

RESULT 24
AAM40292
ID AAM40292 standard; Protein; 864 AA.
XX
AC AAM40292;
XX
DT 22-OCT-2001 (first entry)

XX
DE Human polypeptide SEQ ID NO 3437.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI: 2001-442253/47.
DR N-PSDB: AAI59448.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 5; SEQ ID NO 3437; 10078pp: English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAI42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localized neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemia and
CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 864 AA;

Query Match 7.2% Score 172.5; DB 22; Length 864;
Best Local Similarity 20.0%; Pred. No. 8.9e-06;
Matches 92; Conservative 75; Mismatches 179; Indels 115; Gaps 15;

QY 82 ELDSVKAQLSOKDEKRDQAIIIDTLRDLERNATVESLONLKAEMLCSTLKROMKF 141
DB 385 elddisgeiaqlgrekysleqgdirekeaelrgktsveqelqndldretsslqleaqqkd 444
QY 142 LEORODETKQAREBAH-----RLKCKMKT--MQEILLQSQRSVEEMIRMGVQOSA 193
DB 445 agdrlidemqkalkrlmdsvrgkcgqetqmsslktqigsqesdiksgeaddlnrakse 504


```

FT      /note= "optionally C or G"
FT      Misc-difference 2189
FT      Misc-difference 2301
FT      Misc-difference 2303
FT      /label= "bipartite targeting motif"
FT      /note= "optionally A or T"
XX
XX      US5710022-A.
XX
XX      20-JAN-1998.
XX
XX      24-OCT-1994; 94US-0328254.
XX
XX      24-OCT-1994; 94US-0328254.
XX      22-OCT-1993; 93US-0141239.
XX
XX      (TEXA ) UNIV TEXAS SYSTEM.
XX
XX      Lee W, Zhu X;
XX      PI
XX      DR      WPI: 1998-109817/10.
XX      N-PSDB: AAV09076.
XX
XX      New isolated mitosis protein and gene - useful for, e.g. developing
XX      products for therapy and diagnosis of hyper-proliferative disorders
XX      such as cancers or psoriasis
XX
XX      Claim 1; Column 40-52; 43pp; English.
XX
XX      This is the amino acid sequence for mitosis, a phosphoprotein
XX      necessary for the cell to enter mitosis. The protein's degradation is
XX      also necessary for the cell to advance into the next stages of mitosis.
XX      The mitosis protein, can be used to control the growth of cells. An
XX      anti-mitosis antibody, a mutant or a non-functional analogue of mitosis
XX      can inhibit the mitotic cell cycle by preventing the cells from entering
XX      the M phase, and over expression of mitosis or its functional
XX      equivalent, would inhibit the cycle by preventing cells from leaving the
XX      M phase. Antagonists to this protein can be used to control
XX      hyperproliferative cells in, (e.g. thyroid hyperplasia, Grave's disease,
XX      psoriasis, benign prostatic hypertrophy, Li-Fraumeni syndrome, breast
XX      cancer, sarcomas and other neoplasms, bladder cancer, colon cancer,
XX      lung cancer and various leukemias and lymphomas). Reintroduction or
XX      supplementation of lost mitosis function by introduction of the protein
XX      or nucleic acid encoding the protein into a cell can restore defective
XX      chromosome segregation, which is a marker of progressing malignancy.
XX      Malignant proliferation of cells can then be halted. The protein
XX      can also be used for the detection and diagnosis of hyperproliferative
XX      cells.
XX
XX      SQ      Sequence 2482 AA:
XX
XX      Query Match 7.28; Score 172.5; DB 19; Length 2482;
XX      Best Local Similarity 24.38; Pred. No. 4.1e-05;
XX      Matches 74; Conservative 53; Mismatches 109; Indels 69; Gaps 10;
XX
XX      QY      56 KTIINKLFFDLAEEEN---VLDAEFLKLNELDSVKAQL-----SOK 93
XX      | : | : | | | | | | | | | | | | | | | | | | | | | | | | | |
XX      | : | : | | | | | | | | | | | | | | | | | | | | | | | | | |
XX      1521 kdkvenlerelqmeengelyildaenskaevetlktqieamarslkwyfeldlvtltssek 1560
XX
XX      QY      94 D-----REKRDQAITDTLDTL-----EERNATVESLQNALNKAEMLC 132
XX      | : | : | | | : | | : | | | | | | | | | | | | | | | | | | |
XX      | : | : | | | : | | : | | | | | | | | | | | | | | | | | | |
XX      1581 enltkqgkqglseldklslsfksllekegaeiqkkesktavemlqqlkneav 1640
XX
XX      QY      133 STL---KKQKFLQROD---ETKQAREEAKRLCKMKATTEQJLELLQSORSE----- 179
XX      | : | : | | | | | | | | | | | | | | | | | | | | | | | | | |
XX      | : | : | | | | | | | | | | | | | | | | | | | | | | | | | |
XX      1641 aalcgddelmkateqslidplieehqjrlnsiekiraleadekqkqcvlqqlkesenhad 1700
XX
XX      QY      180 -----VEEMIDMGVGSAAVEQLAVYCVSLKKEKENLKAEKANGELADRLKKDLYSSRS 234
XX      | : | : | | | : | | : | | | | | | | | | | | | | | | | | | |
XX      | : | : | | | : | | : | | | | | | | | | | | | | | | | | | |
XX      1701 llkgrvenlelelatatngnaaleensqgeveclkakiegmtqslrgleldvvltrs 1760
XX
XX      QY      235 KIKTLNTELDQ-----AKLEL--RSAOKDLQSADEITSLRKKSDDPPGNLE-PASATNE 286

```

```

Db      1761 ekenltneqlqgegeriseleinsfenllqkeqekvkmekesstamemlqtlkne 1820
QY      287 TVSRLL 291
Db      1821 rvaal 1825

RESULT 27
ID      AAR9795 standard; Protein; 3248 AA.
XX
XX      AAR9795;
XX
XX      08-OCT-1996 (first entry)
XX
XX      Kinetochore protein CENP-F.
XX
XX      Kinetochore protein; CENP-F; cell cycle; cancer; diagnosis;
XX      autoimmune antibody.
XX
XX      Homo sapiens.
XX
XX      Key      Location/Qualifiers
XX      FH      Domain      1..200
XX      FT      /label= Extended_coiled_structure
XX      FT      280..1350
XX      FT      /label= Extended_coiled_structure
XX      FT      1380..1610
XX      FT      /label= Globular_domain
XX      FT      /note= "Globular domain consists of 2 direct
XX      repeats of 95 amino acids"
XX      FT      1620..1750
XX      FT      /label= Extended_coiled_structure
XX      FT      1850..2990
XX      FT      /label= Extended_coiled_structure
XX      FT      3048..3248
XX      FT      /label= C-terminal_domain
XX      FT      /note= "the C-terminal domain is predicted to
XX      form a proline-rich (10.6%) highly
XX      basic (PI 10) globular domain"
XX
XX      WO9617867-A1.
XX
XX      13-JUN-1996.
XX
XX      08-DEC-1995; 95MO-US16216.
XX
XX      09-DEC-1994; 94US-0353700.
XX
XX      (FOXC-) FOX CHASE CANCER CENT.
XX      (UYTE-) UNIV TECHNOLOGIES INT INC.
XX
XX      Ratner JB, Yen TJ;
XX      WPI: 1996-287116/29.
XX      N-PSDB: AAT34578.
XX
XX      DNA encoding kinetochore protein - used as a marker for the G2 and M
XX      phases of a cell cycle, partic. for detection of malignant diseases
XX
XX      Claim 12; Page 41-54; 72pp; English.
XX
XX      A 372 kDa human kinetochore protein, CENP-F (AAR9795), is detected
XX      by immunofluorescence microscopy only during the G2 and M phases
XX      of a cell cycle. It is the product of a cDNA clone (AAT34578)
XX      isolated from a breast carcinoma cDNA library. Recombinant CENP-F
XX      can be produced by expression in prokaryotic or eukaryotic host
XX      cells. CENP-F can be used to detect autoimmune antibodies to
XX      the protein, which may provide an early diagnosis for the onset
XX      of various malignant diseases. Use of CENP-F as a cell cycle
XX      marker allows the specific detection of G2 and M phase cells.

```


DR N-PSDB; ABL02776.
 XX
 PT New isolated nucleic acid detection reagent for detecting 1000 or more
 PT genes from Drosophila and for elucidating cell signalling and cell-cell
 PT interactions -
 XX
 PS Disclosure; SEQ ID NO 2811; 21pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated nucleic acid detection reagent
 CC capable of detecting 1000 or more genes from Drosophila. The invention is
 CC useful in developmental biology and in elucidating cell signalling and
 CC cell-cell interactions in higher eukaryotes for the development of
 CC insecticides, therapeutics and pharmaceutical drugs. The invention
 CC discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
 CC sequences (ABL01840-ABL16175) and the encoded proteins
 CC (ABBS7737-ABB72072).
 CC The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pcl_sequences.
 CC
 XX
 SQ Sequence 1456 AA;
 .
 Query Match 7.2%; Score 171.5; DB 22; Length 1456;
 Best Local Similarity 21.1%; Pred. No. 2.3e-05;
 Matches 111; Conservative 88; Mismatches 221; Indels 107; Gaps 18;
 QY 15 DHSDDVAH---CGHFFHLOCLQWFEAPSRCTPCROIOVGKTIINKLFFDLAGEE 71
 DB 55 dyghshlvskescakeehymqltdveemrleeknrl-iekkt-----qgtlq 104
 QY 72 NVLDAEFLKNELDSVKAQLSQDKREKRDQAIIIDTLRDTLEERNATVE----- 119
 DB 105 tvgermrnltselctkdmldkirkisvlqrkieniedllkekngqmdamarlsangah 164
 QY 120 --SIQNALNKAEMLCSLKQMKFLEORODETKQAREBANRLKCKMKMTMEQIELLOSQR 177
 DB 165 hsssegalslslealigqkekmgqlrdgrdraehnekqgerl--herevadylkiklraae 222
 QY 178 SEVEEMLRDMGVGSAVEOLAVYCVSLKKEENLK-EARKATGFLA----- 222
 DB 223 seveikqtrleravtererleiklsesqselgkskaelekatcemgrssadwestkqria 282
 QY 223 -----DLKKDIVSSRSKL-----KTINTELDQA-----KLELRSAQRDLQ 258
 DB 283 rlelenarlkhdlerstqgtftrmttsqelddrgeradkasaalrttqgelrvrtgdaae 342
 QY 259 SADOETLSLRKKSDDPG-----NLEPASATNETVSRLVFESPAVEMKPNRLH---Q 308
 DB 343 rareaanaalqekleksgqevyrlaklenagqegeslrgelekagsgvs--rthadrd 398
 QY 309 PPFGEIDILMTTFPVPNPPRQTSGSOHLPRKL--CLEBRASPMQNVLLKKVHKVSKPESQ 366
 DB 399 rafsevekleemertqacalqksglqh--eklqnsldkaevndhldqkdkactenrr 455
 QY 367 LSLGQRCV-----GELDELAGAPPLFIRNAVLGOKOPNRTTASRSSTDVVRIGFD 419
 DB 456 lvlekekltvdydnlgslldkalqga-----armkqeretls--ldtdlrlekle 503
 QY 420 GLGGRYFIQ-PRDTTIIRPVVSKAKSKOKVRIKTVSSASQPKLD 465
 DB 504 ktgyqlgrlqkqrdqfsgdeletlkersesagcllmkaardreamqtd 550
 RESULT 30
 AAY86194
 ID AAY86194 standard; Protein; 866 AA.
 XX
 AC AAY86194;
 XX
 DT 11-APR-2000 (first entry)
 XX
 DE Nuclear transport protein clone hfb2230 protein sequence.

XX
 KW Nuclear transport protein; drug delivery system; visual detection; human;
 KW nuclear transport indicator.
 XX
 OS Homo sapiens.
 XX
 PN WO9964455-A1.
 XX
 PD 16-DEC-1999.
 XX
 PF 04-JUN-1999; 99WO-JP03015.
 XX
 PR 05-JUN-1998; 98JP-0174065.
 PR 14-APR-1999; 99JP-0107262.
 XX
 PA (HELI-) HELIX RES INST.
 XX
 PI Deki N, Yano K;
 XX
 DR WPI; 2000-105872/09.
 DR N-PSDB; AA296752.
 PS Claim 1; Page 62-67; 309pp; Japanese.
 CC This sequence represents the amino acid sequence of a nuclear transport
 CC protein of the invention. The invention relates to peptides with nuclear
 CC transport activity, and also includes similar peptides with the same
 CC transport activity, but with some amino acids deleted, substituted and/or
 CC added. The peptides can be used as carriers for transferring desirable
 CC substances particularly drugs, including nucleic acids and proteins, into
 CC the nucleus in a drug delivery system. The peptides can also be used as
 CC nuclear transport indicators after modification for visual detection.
 CC Drugs can be delivered efficiently with the peptides to a specific target
 CC site. This delivery allows the maintenance of drug concentration,
 CC therapeutic efficacy and a reduction of side-effects of such drugs to be
 CC achieved.
 CC
 XX
 SQ Sequence 866 AA;
 .
 Query Match 7.1%; Score 170.5; DB 21; Length 866;
 Best Local Similarity 20.0%; Pred. No. 1.3e-05;
 Matches 92; Conservative 75; Mismatches 179; Indels 115; Gaps 15;
 QY 82 ELDSVKAQLSQDKREKRDQAIIIDTLRDTLEERNATVESIQNALNKAEMLCSLKQMKF 141
 DB 387 elddisgeiaqlgrekyslqgdldkeeealrqtksvqelqndldretsslqleaqkqd 446
 QY 142 LEORODETKQAREBAN-----RLKCKMKT--MEQIELLOSQSEVEEMLRDMGVGQSA 193
 DB 447 agdldldemdqkalkrlmldsvrqkcdqetqmsslltqldqsgesdlksqgeddlmrakse 506
 QY 194 VEOLAVYCVSLKKEENLKLEARKATGELADRLKKDLVSSSKTLKINTELDQAELLRSA 253
 DB 507 lnr-----lqgeetlqeslqagrvqletllklsldqdelngarsklsglhesrgea 559
 QY 254 QKDLSQADQ-----EITSLRKKS-----DDPGNLEPASATNETVSRL 291
 DB 560 hrslqgydyvldgahgsalldlanlsqvsalaersgfsfgandpdkn-----kal 608
 QY 292 VFES-----PAPVEMKPNRLHQP-----PRG----- 312
 DB 609 lfsntgelhnpdftqcdpftksdpfkxgdpfkqdpfgndpfaeqgtstlbpfggdpfkex 668
 QY 313 DETIDLNTTFDV-----NPPPTOTSGSOH-CLPKKILCLERARSPMQNVLLKKVHKVSKPES 365
 DB 669 dprfsatddfkfkqtkndpftsdpftknpislpkldpfsesdpfsa-----s 716
 QY 366 QLSLGQRCVGEELDELAGAPPLFIRNAVLGOKOPNRTTASRSSTDVVRIGFDLGRT 425

Db 717 svsskgsdfigtldpfgssgf-----nsaegfdqgmkspppsgdfstslgagfsd-d 770
 QY 426 KFIQPRDFTIIR---RPVVKSKAKSKOKRIKRVSSASQPK 463
 Db 771 pfkskqdcplppkppkppkpsgsktpvsgqlgsadipe 811

RESULT 31 AA07031

ID AA07031 standard; Protein: 1752 AA.

AC AA07031;

DT 02-JUL-1999 (first entry)

DE Breast cancer associated antigen precursor sequence.

KW Cancer associated antigen; diagnosis; research; treatment; human;
 breast cancer; colon cancer; gastric cancer; lung cancer;
 prostate cancer.

OS Homo sapiens.

PN WO9904265-A2.

PD 28-JAN-1999.

PF 15-JUL-1998; 98WO-US14679.

PR 22-JUN-1998; 98US-0103322.

PR 17-JUL-1997; 97US-0896164.

PR 10-OCT-1997; 97US-0061599.

PR 10-OCT-1997; 97US-0061765.

PR 10-OCT-1997; 97US-0948705.

PR 11-OCT-1997; 97GB-0021697.

PA (LUDWIG-) LUDWIG INST CANCER RES.

PI Chen Y, Gout I, Gure A, O'Hare M, Obata Y, Old LJ;

PI Pfeundschn M, Sahin U, Scanlan MJ, Stockert E;

PI Tureci O;

DR WPI; 1999-132448/11.

PT New isolated cancer associated nucleic acids and polypeptides -

PT isolated using sera from cancer patients, used to develop products

PT for the diagnosis, monitoring or treatment of cancers

PS Disclosure; Page 409-413; 787pp; English.

XX The invention relates to a method for diagnosing a disorder characterised

CC by expression of a human cancer associated antigen precursor coded for by

CC a nucleic acid molecule (NAM). The method comprises: (a) contacting a

CC biological sample isolated from a subject with an agent that specifically

CC binds to the NAM, an expression product or a fragment of an expression

CC product complexed with an HLA molecule; and (b) determining the

CC interaction between the agent and the NAM or the expression product as a

CC determination of the disorder. The products and methods can be used in

CC the diagnosis, monitoring, research, or treatment of conditions.

CC Characterised by the expression of various cancer associated antigens.

CC The invention provides nucleic acid sequences and encoded polypeptides

CC which are cancer associated antigen precursors expressed in human breast

CC cancer, renal cancer, colon cancer, gastric cancer, prostate cancer and

CC lung cancer.

XX Sequence 1752 AA;

SQ

Query Match 7.1%; Score 170.5; DB 20; Length 1752;
 Best Local Similarity 18.0%; Pred. No. 3.6e-05;
 Matches 93; Conservative 110; Mismatches 210; Indels 103; Gaps 15;

QY 35 IOWFETAPSRCTPCQRIQVQKTKTIINKLFFDLAQEEENVLDAEF----- 78
 Db 395 lqkansateletlnklkvqgelrl-rldyervsgerltvkdqdltrfqnslkelqkqk 453
 QY 79 LKNEELSVAKQLSQKREKRDQAIIIDLRLDEENNAVESIQNLAKAEMIC-----ST 134
 Db 454 veeelnrlkrtasedsckkkleeelegmrslkegalkitnltqlegaslvkrsedd 513
 QY 135 LKKOMKLEORODETQOAREEAEHRLCKMKMTMOELLLLOSRS-----EVE 181
 Db 514 lrgqrdvlgqhlrekgrtqeelnrlsvealtr--qllqegsvkqahlmehfqkale 571
 QY 182 EMIRDMGVQSAVEQLAVYCVSLKKEYENLKE-----ARKATGELADRLKKDLV 230
 Db 572 dkerslneekieletlqsltenltkehlmeelnrlrleyddllrgrseadsknatll 631
 QY 231 SSRSKLTLELTELDAKLELRSAQKDLQSAODEFTSLRKSDPPGNLEPA-----SATN 285
 Db 632 elrsqqlisnrltqlqjlnldlqreerhlrgelqkfgqaleasnrlqesknqctqvq 691
 QY 286 ETYSRLV-----FESPAPVEMNPRHLHOPFGDEIDLNT-----TFDVNTPPNQ 329
 Db 692 ereslllvklkvleqdkarlqledelnrakstleactrvkqllecekqqlnqlnwktq 751
 QY 330 TSGSQHCLPCKLCLERARSP-----MONTLKKVHK-----VSKPESQLS 368
 Db 752 ysakeael-rkleserekeeknslrseletlrgaelkleecrrckkledstretsqle 810
 QY 369 LGGQRCVGELEDELAGAFPLFIRNAVLGQKOPNRTTAESRSTDVVRIGFDGIGRTKFI 428
 Db 811 tersrygreldk-----lrgprygshtretq--ecewtvdsklvfdgrrkkvtam 859
 QY 429 QPRDFTIIRVPVYKSKAKSKOKRIKRVSSASQPKL 464
 Db 860 qlyecqldktltldklkqkky--eevaselqpf 893

RESULT 32

ABG21233

ID ABG21233 standard; Protein: 1948 AA.

AC ABG21233;

DT 18-FEB-2002 (first entry)

DE Novel human diagnostic protein #21224.

KW Human; chromosome mapping; gene mapping; gene therapy; forensic;

KW food supplement; medical imaging; diagnostic; genetic disorder.

OS Homo sapiens.

PN WO200175067-A2.

PD 11-OCT-2001.

PF 30-MAR-2001; 2001WO-US08631.

PR 31-MAR-2000; 2000US-0540217.

PR 23-AUG-2000; 2000US-0649167.

PA (HYSE-) HYSEQ INC.

PI Drmanac RT, Liu C, Tang YT;

DR WPI; 2001-639362/73.

DR N-PSDB; AAS85420.

PT New isolated polynucleotide and encoded polypeptides, useful in

PT diagnostics, forensics, gene mapping, identification of mutations

PT responsible for genetic disorders or other traits and to assess

PT biodiversity -

PS Claim 20; SEQ ID NO 51592; 103pp; English.
XX
CC The invention relates to isolated polynucleotide (I) and
CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
CC and gene mapping, and in recombinant production of (II). The
CC polynucleotides are also used in diagnostics as expressed sequence tags
CC for identifying expressed genes. (I) is useful in gene therapy techniques
CC to restore normal activity of (II) or to treat disease states involving
CC (II). (II) is useful for generating antibodies against it, detecting or
CC quantitating a polypeptide in tissue, as molecular weight markers and as
CC a food supplement. (II) and its binding partners are useful in medical
CC imaging of sites expressing (II). (I) and (II) are useful for treating
CC disorders involving aberrant protein expression or biological activity.
CC The polypeptide and polynucleotide sequences have applications in
CC diagnostics, forensics, gene mapping, identification of mutations
CC responsible for genetic disorders or other traits to assess biodiversity
CC and to produce other types of data and products dependent on DNA and
CC amino acid sequences. ABG00010-ABG30377 represent novel human
CC diagnostic amino acid sequences of the invention.
CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pcl_sequences.
XX
SQ Sequence 1948 AA:

Query Match 7.1%; Score 170.5; DB 22; Length 1948;

Best Local Similarity 20.5%; Pred. No. 4.2e-05; Mismatches 169; Indels 51; Gaps 11;

Matches 78; Conservative 83; Mismatches 169; Indels 51; Gaps 11;

OY 55 KKTITNKLFPDLAQBENNVDAEFLKNELDVSKAQLSOKDRERDSQAIIIDTLRDLTEER 114
DB 1273 qqrllnel---saqkarlhsegsfqrldedkdamwqslsrgyqatfqleelkrqdee 129
OY 115 NATVESIQNALNKAEMICSTLKKOMFLERODETKQAREAHRLCKMKTMEQIELL-- 172
DB 1330 tkakstahalgarnrdcdllregeeegeakaelqrgmekanasevawrtkyetdaigr 1389
OY 173 ---LOSRSVEEMIRDMVGOSAVBQLAVYSIKKEYENLK-----EARKATG 219
DB 1390 teeleekkklaqrigd---aeehveavnskcaslektqrlqnevedlmdversnaac 1446
OY 220 ELADRLKK--DLVSSRSKLTNTLTDQAKLELRSAGKQDSADOETLSLRKSDPPGN 277
DB 1447 laidkkgrndkylaeakqg----yeetgaeeleasgkeersstelfxknayeesldh 1501
OY 278 LEPASATNEVSRVLESPAPVEMANPRLHQPPEGEID--LNTTPDVNTPPTOTSGSQHC 336
DB 1502 letlkrenknlgqelsdltegiaegghh-----elkvkkqjldhekselqts----- 1550
OY 337 LPRKLCLEARRSPMONVLLKVKHVKSPESQSLSGGRCVGELEDELAGAPFLIRNAV-L 395
DB 1551 -----leeaaaleheegkllirqlnelqvkseldrkaekdeel---dqklrnllrv 1600
OY 396 GOKQPNRTAESRSSTDVARI 416
DB 1601 vesmgstldeetrndalrli 1621

RESULT 33
AAAM79838
ID AAM79838 standard; Protein; 1963 AA.

XX
XX AAM79838;

XX
XX 06-NOV-2001 (first entry)

DE
XX Human protein SEQ ID NO 3484.

KW Human; cytokine; cell proliferation; cell differentiation; gene therapy;
KW vaccine; peptide therapy; stem cell growth factor; haematopoiesis;
KW tissue growth factor; immunomodulatory; cancer; leukaemia;

KW nervous system disorder; arthritis; inflammation.
XX
OS Homo sapiens.
XX
PN WO200157190-A2.
XX
PD 09-AUG-2001.
XX
PF 05-FEB-2001, 2001WO-US04098.
XX
PR 03-FEB-2000, 2000US-0496914.
PR 27-APR-2000, 2000US-0560875.
PR 20-JUN-2000, 2000US-0598075.
PR 19-JUL-2000, 2000US-0620325.
PR 01-SEP-2000, 2000US-0654936.
PR 15-SEP-2000, 2000US-0663561.
PR 20-OCT-2000, 2000US-0693325.
PR 30-NOV-2000, 2000US-0728422.
XX
PA (HYSB-) HYSBO INC.
XX
PI Tang YT, Liu C, Drmanac RT, Asundi V, Zhou P, Xu C, Cao Y, Ma Y;
PI Zhao QA, Wang D, Wang J, Zhang J, Ren F, Chen R, Wang ZW;
PI Xue AJ, Yang Y, Wejhrman T, Goodrich R;
XX
DR WPI: 2001-476283/51.
DR N-PSDB; AAK52971.
XX
PT Nucleic acids encoding polypeptides with cytokine-like activities,
XX useful in diagnosis and gene therapy -
XX
PS Claim 20; Page 354-355; 6221pp; English.

XX The invention relates to polynucleotides (AAK51456-AAK53435) and the
XX encoded polypeptides (AAM78323-AAK80302) that exhibit activity relating to
XX cytokine, cell proliferation or cell differentiation or which may induce
XX production of other cytokines in other cell populations. The
XX polynucleotides and polypeptides are useful in gene therapy, vaccines or
XX peptide therapy. The polypeptides have various cytokine-like activities,
XX e.g. stem cell growth factor activity, haematopoiesis regulating
XX activity, tissue growth factor activity, immunomodulatory activity and
XX activity/inhibin activity and may be useful in the diagnosis and/or
XX treatment of cancer, leukaemia, nervous system disorders, arthritis and
XX inflammation.
XX Note: Records for SEQ ID NO 2110 (AAK52581), 2111 (AAK52582) and 3666
XX (AAM60020) are omitted as the relevant pages from the sequence listing
XX were missing at the time of publication.

SQ Sequence 1963 AA:

Query Match 7.1%; Score 170.5; DB 22; Length 1963;

Best Local Similarity 20.4%; Pred. No. 4.3e-05; Mismatches 167; Indels 143; Gaps 22;

Matches 105; Conservative 99; Mismatches 167; Indels 143; Gaps 22;

OY 65 DLAQEENNVDAEFLKNELDVSKAQLSOKDRERDSQAIIIDTLRDLTEERNATVES-LQN 123
DB 1138 dlygeele-alkte-ledtdlstaag--qelrstrge--vnlkktleeeaktheagdi 1191
OY 124 ALNKAEMICSTLKKOMFLERODETKQAREAHRLCKMKTME-----OIELLOS 175
DB 1192 mrqkhsqaveelaegf-----eqtkrvkanlekak---qltenergelanevkvllg 1241
OY 176 -----QRSEVEEMIRDMCV---GGSAYBQLAVYCVSLKKEYENLKEARKAAGELADRL 225
DB 1242 kgdsehkrrkveaqelqvkfnegervrteladkvtklqveldvntyllsgdsksk 1301
OY 226 KRDVSSRSKLLK-----TLNTELDQAKLELRSAGKQDSADOE----- 263
DB 1302 tkdfsaesqldtqgelqgeemrqklsistklkyvedeknsfregleeeeeeaknhlek 1361
OY 264 -----ITSLRKSDPPGNLEPASATN-----ETVSRLVFESPA---PYEMNMPRI 306

Db 1362 laatlhaqadmkkkmedsvgcletaeevkrk1qkldleglsqrheekvaaydklektr1 1421
 QY 307 HOPFGEIDLN-----TFDVNTPTPTSGSOH----- 335
 Db 1422 qgelddl1vldhrgsaclnekqkfkfdqlaeekclisakyaeeadraeaareketka 1481
 QY 336 -----CLPKKLCLERA-----RSPMQNVL-----KKVHKVSKPESOLSLGQRC- 374
 Db 1482 ls1arlaeameqkaelerlnkqfitemedlmskddvgksvheleekskraieqveemk 1541
 QY 375 --VGEDELDELAGAPPLFIRNAVLGQKOPNRTAESRSTDVVRIGFDLGGRKFTIOPRD 432
 Db 1542 tqleedeledqatedakrliev-----n1qamkaqferd-----lqgrdeqseek 1587
 QY 433 TTIRPV-PVKSRAKSKOKVRIKTVSSASOPKLD 465
 Db 1588 kqivryremeealeederkqgrsmavaarkklend 1621
 RESULT 34
 ID ABG27218 standard; Protein; 2918 AA.
 AC ABG27218;
 DT 18-FEB-2002 (first entry)
 XX
 DE Novel human diagnostic protein #27209.
 KW Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder.
 XX Homo sapiens.
 OS
 PN W0200175067-A2.
 PD 11-OCT-2001.
 PF 30-MAR-2001; 2001MO-US08631.
 PR 31-MAR-2000; 2000US-0540217.
 PR 23-AUG-2000; 2000US-0549167.
 XX
 PA (HYSE-) HYSEQ INC.
 PI Drmanac RT, Liu C, Tang YT;
 DR WPI, 2001-639362/73.
 DR N-PSDB; AAS91405.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity -
 PS Claim 20; SEQ ID NO 57577; 103bp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and

CC amino acid sequences. ABG00010-ABG30377 represent novel human
 CC diagnostic amino acid sequences of the invention.
 CC Note: The sequence data for this patent did not appear in the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pcl_sequences.
 XX
 SQ Sequence 2918 AA;
 Query Match 7.18; Score 170.5; DB 22; Length 2918;
 Best Local Similarity 18.0%; Pred. No. 7.6e-05;
 Matches 93; Conservative 110; Mismatches 210; Indels 103; Gaps 15;
 QY 35 IOMETAPSRTPCPCRFVCGKTTINKLPFDLQAEENVLDAEF----- 78
 Db 1561 lqknsateclinklkqgeqeltrl-rldyersqetvtdqddltrfnskelqkqk 1619
 QY 79 LKNELDSVKAQLSQDKREKDSQAIIPTLDLTERNATVESLONALNKAEMLC---ST 134
 Db 1620 veeelnrlkrtasedckrkkleeelegmrtrslkeqakltnltqlegaslvkksedd 1679
 QY 135 LKKQMKFLEQRQDPTKQAREEARLKKCKMKTMEQIELLOSQR-----EVE 181
 Db 1680 lrgqrdvldghlrekgfqlgeelrlssevealrf--qlqgesvkgahlrnehfgkaje 1737
 QY 182 EMIRDMGVGSAVPOLAVYCVSLKKEYNLKE-----ARKATGELADRLKKDLV 230
 Db 1738 dksrlneskeleerlqslentlenlkenhleelnrlleyddltrrseedscknatil 1797
 QY 231 SSRSKLTMLNTELDQAKLELSAQKDLQADQETTSLRKSDPPGNLEPA-----SATN 285
 Db 1798 elrsqqlsmnrtlelqglindlqgrentlrgelrkgfkqgleasnrlgesknqctgvq 1857
 QY 286 ETYSRLV-----FESPAPEVMANRRLHQPFGDEIDLNT-----TFDVNTPTPTQ 329
 Db 1858 eresllvklvleqdkarlgledelnraksleaelrvkqrlceekqqlndinqktt 1917
 QY 330 TSGSOHCLPKKLCLEARSP-----MONVLKKVHK-----VSKPESOLS 368
 Db 1918 ysrlkeael-rklseereeseknslrselelqaeikrlleerckrlledstretqslq 1976
 QY 369 LGGRCVGEDELDELAGAPPLFIRNAVLGQKOPNRTAESRSTDVVRIGFDLGGRKFTI 428
 Db 1977 tetsrygreidk-----lrgrypsnreigt--ecetvdtstslvfdglkkrvtam 2025
 QY 429 QPRDPTTIRPVVSKAKSKOKVRIKTVSSASOPKL 464
 Db 2026 qlyecqjldktldklkqkksv--eevaseigpfl 2059
 RESULT 35
 AAR42818
 ID AAR42818 standard; Protein; 1093 AA.
 AC AAR42818;
 DT 27-APR-1994 (first entry)
 XX
 DE TMF.
 KW TMTA modulating factor; TMF; transcription; TMTA box; promoter; HIV-1;
 KW human immunodeficiency virus-1; short arm; human chromosome 3; p12-p13;
 XX translocation; cancer.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Region 437..850
 FT Region /label= TATA binding region
 FT Region 769..777
 FT /note= "Ubiquitin-mediated protein degradation
 FT Region 454..614 consensus sequence homology region"

Db 369 eggmmeamsdrvkatqaeqlsnelaterstaqknesarqqlergnkelrsklhemea 428
 QY 160 -KCKMK-TMEOIELLOSQSEVEEMIRDMGVGOSAVEQLAVYCVSLKKEKENLEARKA 217
 Db 429 vskfksltlaaleakqleeqveqaerek---qaalksIkqdkkIkellIqvederk- 484
 QY 218 TGEIADRLKKDLVSSRSKLTINTELDOAKLELRSQKDLQSDAQDETTSLRKSDPPGN 277
 Db 485 ---maeqykegaekgnarvqkIkrgleaeae-----sgrlnanrrkIq---re 527
 QY 278 LEPASATNETVSRVLFESPAVEMNRLHOPP 310
 Db 528 Ideatesneamgr-----evnalkskIrgpp 553

RESULT 40
 AAR66929
 ID AAR66929 standard; Protein: 576 AA.
 AC AAR66929;
 XX
 DT 01-SEP-1995 (first entry)
 XX
 DE AMWL chromosome inv(16) product.
 XX
 KW AMWL; acute myelomonocytic leukemia; chromosome-16; inversion;
 KM inv(16); CBF-beta; CBFb gene; transcription factor; myosin; MYH11;
 KM SMHC.
 XX
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 FT Peptide 1..164 /label= CBFb
 FT Peptide 165..576 /label= MYH11
 FT
 XX
 PN MO9504067-A.
 PD 09-FEB-1995.
 XX
 PF 26-JUL-1994; 94WO-US08530.
 XX
 PR 29-JUL-1993; 93US-0099869.
 XX
 PA (UNMT) UNIV MICHIGAN.
 PA (TEXA) UNIV TEXAS SYSTEM.
 XX
 PI Claxton D, Collins FS, Liu P, Siciliano MJ;
 XX
 DR WPI: 1995-082178/11.
 DR N-PSDB: AAQ84588.
 XX
 PT Novel DNA spanning the pericentric inversion of chromosome 16 -
 PT for the screening of acute myeloid leukaemia
 XX
 PS Claim 4; Page 28-30; 78pp; English.
 XX
 CC PCR was performed on total cellular RNA from 5 AMWL patients having
 CC a pericentric inversion of chromosome-16, M4Eo subtype. Sequencing
 CC showed the inv(16) fusion to comprise a sequence from the CBFb
 CC gene, encoding a novel transcription factor, and the MYH11 gene,
 CC encoding smooth muscle myosin heavy chain. In 3 patients, nt 1-492
 CC of the CBFb gene were fused to nt 1921 of MYH11 (shown in
 CC AAQ84588; predicted aa sequence in AAR66929). Probes based on inv(16)
 CC can be used for diagnosis of AMWL.
 XX
 SQ Sequence 576 AA;

Query Match 7.0%; Score 168.5; DB 16; Length 576;
 Best Local Similarity 23.8%; Pred. No. 1.1e-05;
 Matches 65; Conservative 54; Mismatches 99; Indels 55; Gaps 10;

QY 65 DLAOEENVLDAEFLKNELDVKAOLSO-----DREKRSOATIDTLPDTEE 113
 Db 326 dlmqlgediaaerarkqadlkeeeleaeasslsgrnaIgdetrleaaIqleeelee 385
 QY 114 RMTVESLQNALNK---AEMLC-----STLKQMKFLEORODETKQAREAHRL--- 159
 Db 386 eggmmeamsdrvkatqaeqlsnelaterstaqknesarqqlergnkelrsklhemea 445
 QY 160 -KCKMK-TMEOIELLOSQSEVEEMIRDMGVGOSAVEQLAVYCVSLKKEKENLEARKA 217
 Db 446 vskfksltlaaleakqleeqveqaerek---qaalksIkqdkkIkellIqvederk- 501
 QY 218 TGEIADRLKKDLVSSRSKLTINTELDOAKLELRSQKDLQSDAQDETTSLRKSDPPGN 277
 Db 502 ---maeqykegaekgnarvqkIkrgleaeae-----sgrlnanrrkIq---re 544
 QY 278 LEPASATNETVSRVLFESPAVEMNRLHOPP 310
 Db 545 Ideatesneamgr-----evnalkskIrgpp 570

Search completed: September 4, 2002, 16:09:06
 Job time: 8130 sec
